2022
Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone?
Rodriguez JV, Tormey CA. Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone? Transfusion And Apheresis Science 2022, 61: 103402. PMID: 35288056, DOI: 10.1016/j.transci.2022.103402.Peer-Reviewed Original ResearchConceptsTransfusion-associated graftTA-GVHDHost diseaseCellular blood productsHigh mortality rateWhite blood cellsBlood productsEffective treatmentMortality rateTransfusion communityHigh mortalityMedical literatureBlood cellsDiseaseDevastating diseaseGraftLeukocytesLeukoreductionQuantitative reductionHospitalMortality
2016
Understanding red blood cell alloimmunization triggers
Hendrickson JE, Tormey CA. Understanding red blood cell alloimmunization triggers. Hematology 2016, 2016: 446-451. PMID: 27913514, PMCID: PMC6142457, DOI: 10.1182/asheducation-2016.1.446.Peer-Reviewed Original ResearchConceptsRBC alloimmunizationRed blood cellsRisk factorsBlood cellsWhite blood cellsBlood group antigensPregnancy outcomesAlloantibody formationRBC alloantibodiesRBC transfusionRecipient factorsTransfusion safetyAlloimmunizationAnimal modelsHuman studiesPrevention strategiesDonor plasmaDanger signalsParticular antigenGroup antigensAntigenTransfusionPregnancyNonrespondersCells
2015
Riboflavin‐ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells
Tormey CA, Santhanakrishnan M, Smith NH, Liu J, Marschner S, Goodrich RP, Hendrickson JE. Riboflavin‐ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells. Transfusion 2015, 56: 863-872. PMID: 26643781, DOI: 10.1111/trf.13432.Peer-Reviewed Original ResearchConceptsWhite blood cellsFresh whole bloodPathogen reduction treatmentAlloimmune responseWhole bloodRBC antigensSyngeneic RBCsNegative direct antiglobulin testBlood cellsRBC antigen expressionRecipient alloimmune responsesDirect antiglobulin testMurine red blood cellsPathogen inactivation treatmentPosttransfusion RBC recoveryKEL RBCsRBC alloimmunizationImmunogenic neoantigensRed blood cellsAntiglobulin testBlood donorsImmune responseAntigen expressionHours posttransfusionHuman antigens
2010
In vitro and in vivo evaluation of a whole blood platelet‐sparing leukoreduction filtration system
Snyder EL, Whitley P, Kingsbury T, Miripol J, Tormey CA. In vitro and in vivo evaluation of a whole blood platelet‐sparing leukoreduction filtration system. Transfusion 2010, 50: 2145-2151. PMID: 20497514, DOI: 10.1111/j.1537-2995.2010.02701.x.Peer-Reviewed Original ResearchConceptsRed blood cellsWhite blood cellsAutologous plateletsTransfusion productsBlood cellsAdverse clinical sequelaeCPD plasmaProduction of plateletsResidual white blood cellsClinical sequelaeDrug Administration requirementsHospital useVivo efficacyLeukoreduction filtersBlood centersStudy designVivo evaluationLR productsVivo characteristicsPlateletsRBC recoveryAdministration requirementsVitroSurvival ratioFDA guidelines